Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/31652| Title: | Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. | |
| Authors: | ||
| Keywords: | ||
| Mesh: | ||
| Issue Date: | 19-Oct-2017 | |
| Citation: | Neuro-oncology.2017 Oct;(19)11:1522-1531 | |
| Abstract: | We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. | |
| PMID: | 28575464 | |
| URI: | https://hdl.handle.net/20.500.12530/31652 | |
| Rights: | openAccess | |
| Appears in Collections: | Hospitales > H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PMC5737732.pdf | 685.47 kB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.